Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric A Singer

Showing results (121-130 of 253) with videos related to

Pageof 26
Sort By:
Translational Cancer Research|December 19, 2024
Integrating artificial intelligence in renal cell carcinoma: evaluating ChatGPT's performance in educating patients and traineesJ Patrick Mershon, Tasha Posid, Keyan Salari, et al.
Journal of Cancer|May 17, 2013
Low Grade Micropapillary Urothelial Carcinoma, Does It Exist? - Analysis of Management and Outcomes from the Surveillance, Epidemiology and End Results (SEER) DatabaseSrinivas Vourganti, Andrew Harbin, Eric A Singer, et al.
Current Opinion in Oncology|March 28, 2012
Active surveillance for prostate cancer: past, present and futureEric A Singer, Aradhana Kaushal, Baris Turkbey, et al.
Urologic Oncology|July 2, 2025
Concordance between clinical and pathologic staging of larger (cT2a-b) and more invasive (cT3a) renal cell carcinomaTaylor Goodstein, Rajvi Goradia, Arnav Srivastava, et al.
Current Urology Reports|January 6, 2021
From Diagnosis to Therapy-PET Imaging for Pheochromocytomas and ParagangliomasHiren V Patel, Arnav Srivastava, Murray D Becker, et al.
Journal of Cancer Metastasis and Treatment|April 24, 2026
Perioperative therapies for metastatic renal cell carcinomaMatthew P Lierz, Allen Enrique D Siapno, Adam Khorasanchi, et al.
European Urology|December 3, 2014
Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinibMark N Stein, Kim M Hirshfield, Hua Zhong, et al.
Expert Opinion on Drug Metabolism & Toxicology|November 16, 2017
Androgen deprivation therapy for the treatment of prostate cancer: a focus on pharmacokineticsCharles F Polotti, Christopher J Kim, Nadiya Chuchvara, et al.
Clinical Genitourinary Cancer|September 17, 2025
Impact of Upstaging From cT2a-b to pT3a on Overall Survival Among Patients With Renal Cell CarcinomaTaylor Goodstein, Rajvi Goradia, Arnav Srivastava, et al.
Clinical Genitourinary Cancer|March 18, 2026
Retraction notice to " Impact of Upstaging From cT2a-b to pT3a on Overall Survival Among Patients With Renal Cell Carcinoma"[Clinical Genitourinary Cancer 23/6 (2025) 102422]Taylor Goodstein, Rajvi Goradia, Arnav Srivastava, et al.
Pageof 26

Showing results (121-130 of 253) with videos related to

Sort By:
Pageof 26
Translational Cancer Research|December 19, 2024
Integrating artificial intelligence in renal cell carcinoma: evaluating ChatGPT's performance in educating patients and traineesJ Patrick Mershon, Tasha Posid, Keyan Salari, et al.
Journal of Cancer|May 17, 2013
Low Grade Micropapillary Urothelial Carcinoma, Does It Exist? - Analysis of Management and Outcomes from the Surveillance, Epidemiology and End Results (SEER) DatabaseSrinivas Vourganti, Andrew Harbin, Eric A Singer, et al.
Current Opinion in Oncology|March 28, 2012
Active surveillance for prostate cancer: past, present and futureEric A Singer, Aradhana Kaushal, Baris Turkbey, et al.
Urologic Oncology|July 2, 2025
Concordance between clinical and pathologic staging of larger (cT2a-b) and more invasive (cT3a) renal cell carcinomaTaylor Goodstein, Rajvi Goradia, Arnav Srivastava, et al.
Current Urology Reports|January 6, 2021
From Diagnosis to Therapy-PET Imaging for Pheochromocytomas and ParagangliomasHiren V Patel, Arnav Srivastava, Murray D Becker, et al.
Journal of Cancer Metastasis and Treatment|April 24, 2026
Perioperative therapies for metastatic renal cell carcinomaMatthew P Lierz, Allen Enrique D Siapno, Adam Khorasanchi, et al.
European Urology|December 3, 2014
Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinibMark N Stein, Kim M Hirshfield, Hua Zhong, et al.
Expert Opinion on Drug Metabolism & Toxicology|November 16, 2017
Androgen deprivation therapy for the treatment of prostate cancer: a focus on pharmacokineticsCharles F Polotti, Christopher J Kim, Nadiya Chuchvara, et al.
Clinical Genitourinary Cancer|September 17, 2025
Impact of Upstaging From cT2a-b to pT3a on Overall Survival Among Patients With Renal Cell CarcinomaTaylor Goodstein, Rajvi Goradia, Arnav Srivastava, et al.
Clinical Genitourinary Cancer|March 18, 2026
Retraction notice to " Impact of Upstaging From cT2a-b to pT3a on Overall Survival Among Patients With Renal Cell Carcinoma"[Clinical Genitourinary Cancer 23/6 (2025) 102422]Taylor Goodstein, Rajvi Goradia, Arnav Srivastava, et al.
Pageof 26